Trials / Conditions / Escherichia Coli Infections

Escherichia Coli Infections

12 registered clinical trials studyying Escherichia Coli Infections.

Status	Trial	Sponsor	Phase
Completed	Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals NCT06252428	Suez Canal University	—
Terminated	Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria NCT03869593	Centre Hospitalier Universitaire de Nice	—
Unknown	Effects of Nutritional Fat on the Growth of Intestinal E. Coli NCT03800147	University of Zurich	N/A
Unknown	Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in P NCT02729116	Khon Kaen University	Phase 2 / Phase 3
Completed	Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli NCT02541695	NIZO Food Research	N/A
Completed	Epidemiology of ST131 in Besançon University Hospital NCT02853708	Centre Hospitalier Universitaire de Besancon	—
Completed	Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms NCT01324726	American University of Beirut Medical Center	—
Completed	Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care NCT03303937	Hôpital Louis Mourier	—
Completed	Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 NCT01406288	University Hospital, Bordeaux	—
Terminated	Enteroaggregative E.Coli (EAEC) NCT00362869	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units NCT00167999	Wyeth is now a wholly owned subsidiary of Pfizer	—
Completed	Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Co NCT00167986	Wyeth is now a wholly owned subsidiary of Pfizer	—